Jones R N
Division of Medical Microbiology, College of Medicine, University of Iowa, Iowa City, USA.
Am J Health Syst Pharm. 1995 Mar 15;52(6 Suppl 2):S29-33. doi: 10.1093/ajhp/52.6_Suppl_2.S29.
The in vitro antimicrobial spectrum of piperacillin-tazobactam is described and the results of clinical trials are summarized. Injectable products combining a beta-lactam antibiotic with a beta-lactamase inhibitor have a broad spectrum of activity, principally influenced by the potency of the beta-lactam. Piperacillin-tazobactam can be used for the treatment of infections caused by gram-negative, gram-positive, aerobic, and anaerobic bacteria. Appropriate indications include infections caused by mixed flora, such as gynecologic, intra-abdominal, and surgical wound infections. Other infections that appear responsive include those associated with human and animal bites, ischemic or diabetic foot infections, infected ischemic or pressure ulcers, and lower-respiratory-tract infections. Piperacillin-tazobactam has been reported to be superior to ticarcillin-clavulanate in community-acquired lower-respiratory-tract infections and superior to imipenem-cilastatin (at 1.5 g/day of imipenem) in intra-abdominal infection.
描述了哌拉西林-他唑巴坦的体外抗菌谱，并总结了临床试验结果。将β-内酰胺抗生素与β-内酰胺酶抑制剂联合使用的注射用产品具有广泛的活性谱，主要受β-内酰胺效力的影响。哌拉西林-他唑巴坦可用于治疗由革兰氏阴性菌、革兰氏阳性菌、需氧菌和厌氧菌引起的感染。适当的适应症包括由混合菌群引起的感染，如妇科、腹腔内和手术伤口感染。其他似乎有反应的感染包括与人类和动物咬伤、缺血性或糖尿病足感染、感染性缺血性或压疮以及下呼吸道感染相关的感染。据报道，哌拉西林-他唑巴坦在社区获得性下呼吸道感染中优于替卡西林-克拉维酸，在腹腔内感染中优于亚胺培南-西司他丁（亚胺培南每日1.5 g）。
